FOSUN HEALTH Logo

Liver Cancer Overview

catalogue

Liver Cancer Overview

Liver Cancer Overview

Liver cancer is quiet, and it usually grows in a liver that was already damaged. This page explains what the disease is and how it behaves — then opens into six full guides covering symptoms, diagnosis, treatment, causes, prevention, and the practical questions international patients ask most.

Liver Cancer Overview
  • new liver cancer cases worldwide each year (WHO)

  • of the world's new cases occur in China

  • TACE procedures at Guangzhou Fosun Hospital, 2023–2025

  • from complete records to a personalized MDT plan

What liver cancer is

Primary liver cancer begins inside the liver itself — most often in hepatocytes, the organ's main working cells — rather than arriving there from somewhere else. That distinction is not academic: cancer that has spread to the liver from the bowel, breast or lung is a different disease with different treatment, and it is not what this page describes.

What makes liver cancer unusual is the soil it grows in. In most patients the liver was already damaged long before the tumour appeared — by chronic hepatitis B or hepatitis C, by years of heavy drinking, or by metabolic liver disease — and frequently by established cirrhosis. A scarred liver is a liver in which cells are repeatedly injured, lost and replaced, and that cycle of damage and repair is what eventually allows a malignant clone to take hold. The full list is set out in causes and risk factors.

The liver compounds the problem in two ways. Its substance has no pain-sensitive nerves, and it keeps a large functional reserve, so a tumour can grow to a considerable size before producing anything a person would notice. Symptoms are therefore a late signal, not an early one — which is why surveillance imaging, and not symptom-watching, is how this cancer is meant to be found. What to look for if something has already changed is covered in symptoms and early warning signs.

A diagnosis consequently raises three questions that must all be answered before treatment is chosen. How far has the tumour gone? That is the stage. How much working liver is left? That is the functional reserve, usually scored with Child-Pugh. What is driving the tumour? That is the biology — the pathology and molecular findings. Liver cancer care is built on those three axes together, never on the diagnosis alone.

Hepatocellular carcinoma and bile-duct cancer: two diseases, two plans

Most primary liver cancers are hepatocellular carcinoma (HCC), which arises from liver cells. A minority begin instead in the small bile ducts inside the liver and are called intrahepatic cholangiocarcinoma. They are not variations of one illness: they grow differently, are staged differently and respond to different drugs, so the first thing pathology establishes is which one is present.

Hepatocellular carcinoma (HCC) Intrahepatic cholangiocarcinoma
How common The large majority of primary liver cancers A minority of cases, but rising in several regions
Where it starts Liver cells (hepatocytes) The small bile ducts inside the liver
Background liver Usually already damaged — hepatitis B or C, alcohol, metabolic disease, cirrhosis Often an otherwise normal liver
How it behaves Often multifocal; tends to invade the portal vein and to stay in the liver longer Spreads along bile ducts and to lymph nodes earlier
Main treatments Resection or transplant, ablation, TACE and related interventional therapies, radiosurgery, targeted and immunotherapy drugs Surgery where possible, chemotherapy, targeted therapy, immunotherapy, radiotherapy; interventional treatment in selected cases
Targetable findings Fewer classical driver mutations; immunotherapy combinations are central More frequent — including FGFR2 fusions and IDH1 mutations in a subset of tumours

Why the distinction changes the first step. In a patient with cirrhosis, a typical HCC can often be diagnosed from contrast imaging alone, without a needle. Cholangiocarcinoma usually cannot, because its imaging pattern overlaps with other lesions — so tissue is needed. And because a subset of bile-duct cancers carries an alteration with a matching drug, tumour tissue may be tested for those targets. The same patient, with the same sized tumour in the same place, can therefore follow two quite different diagnostic paths depending on which cancer it is.

What the stages mean

Liver cancer is staged differently from most cancers, because the plan has to respect two things at once: the tumour and the liver it sits in. The system most widely used internationally is the Barcelona Clinic Liver Cancer (BCLC) classification, which combines tumour extent, liver function and general fitness. Chinese guidelines use a related national staging system; the underlying logic is the same.

Stage What it means What treatment is usually aiming for
Very early A single small tumour in a liver that is still working well Cure. Removal of the tumour by surgery or ablation, sometimes transplantation
Early One tumour, or up to three, within a size limit; liver function preserved Cure or long control. Resection, transplantation, or ablation where surgery is not suitable
Intermediate Multiple tumours confined to the liver, without invasion of the portal vein or spread beyond it Control and conversion. Interventional treatment such as TACE, often repeated, sometimes leading to surgery
Advanced Tumour has entered the portal vein, or has spread to lymph nodes, bone or elsewhere Long-term control. Targeted therapy and immunotherapy, with radiotherapy or interventional treatment at specific sites when useful
End stage Liver function is failing and the patient's general condition limits treatment Best supportive care and control of symptoms, with treatment aimed at comfort and quality of life

Two sentences deserve to be read twice. First, the stage is not decided by the tumour alone: two patients with an identical tumour can receive completely different recommendations because one liver is compensating well and the other is not. Preserving liver function is part of the treatment, not a side consideration. Second, stage is not fixed by the first scan. If a tumour responds to interventional or drug treatment, an initially inoperable cancer can sometimes shrink enough to be removed — which is why a case like this belongs in front of a multidisciplinary panel rather than a single department.

What advanced stage does and does not mean. It does mean the cancer cannot be removed by an operation today. It does not mean there is nothing to offer: with modern systemic therapy, a proportion of advanced liver cancers are managed over years, with treatment cycles, periodic scans and periods of ordinary life in between.

Why liver function and tumour biology matter as much as stage

In most cancers, the stage tells you the most important thing. In liver cancer it tells you only part of it. The first reason is functional: nearly every available treatment takes something out of the liver, whether that is a segment of tissue, a blood supply, or the liver's tolerance for a drug. A plan that destroys the tumour but leaves the patient in liver failure has failed. That is why the same tumour can be treated aggressively in one patient and conservatively in another who has the same stage but poorer reserve.

The second reason is biological. Tumour tissue is examined for features that predict how the disease will behave and which drugs are worth using. In hepatocellular carcinoma, this increasingly means looking for markers of immune responsiveness and for alterations that later-line drugs can target; in bile-duct cancer, tests may look for FGFR2 fusions or IDH1 mutations, which change the treatment entirely. When the first systemic treatment stops working, repeating the question — what is driving this now? — is more useful than switching drugs at random.

Third, blood tumour markers such as AFP and PIVKA-II support the diagnosis and then track response over time, while a liver function panel shows what the liver itself is doing. Read together with imaging, they tell the team whether a treatment is working and whether it is being tolerated. How these tests are put together into a diagnosis is set out in the diagnosis guide, and how they change the treatment plan in the treatment guide.

Why international patients come to China for liver cancer treatment

Four practical reasons come up most often in conversations with patients and their families. None of them is exotic; all of them are consequential.

Volume, and the pattern recognition that comes with it

Close to half of the world's liver cancer cases occur in China, with roughly 900,000 new diagnoses worldwide each year and the largest share of them here. Teams meet this disease daily, in every stage and presentation — including the vascular and multifocal patterns that are seen only occasionally in lower-volume centres.

The whole pathway under one roof

Surveillance ultrasound and AFP testing, multiphase contrast CT and MRI, pathology and molecular testing, an interventional oncology suite, robotic surgery, breath-tracking radiosurgery and systemic therapy all sit inside the same hospital network. Diagnosis and treatment do not have to be assembled across several institutions or countries.

Earlier access to newer drugs

Drug development for liver cancer in China has moved quickly, and combination protocols developed here — of which the best known is camrelizumab with apatinib — are recognised in NCCN, ESMO and CSCO guidelines. Later-line targeted drugs and bispecific antibodies are in routine use, and mutation-matched clinical trials are an option when standard treatment has been exhausted.

One decision, made by seven specialties

Hepatobiliary surgery, interventional radiology, medical oncology, radiation oncology, hepatology, radiology and pathology review the case together and issue a single plan — within 48 hours of your records being complete — rather than a plan that depends on which department you happened to visit first.

What we do not promise. Treatment abroad is not a shortcut, and not every patient is better off travelling. Our first step for international patients is a written review of records, which is often the most useful thing we can provide even if no trip follows.

Frequently Asked Questions

Can liver cancer be cured?

Sometimes, and predictably so when it is found early. A small tumour in a liver that still works well can be removed or destroyed with cure as the goal, and this is the reason surveillance programmes exist. For larger or multifocal disease the aim is usually long-term control, and interventional treatment can sometimes shrink a tumour enough to make removal possible later. Because most liver cancers grow in damaged livers, every plan here weighs cancer control against protecting the liver you have left.

The tumour has grown into the portal vein. Are there still options?

Yes. A portal vein tumour thrombus is a serious finding, but it is not the end of the treatment road. Stereotactic radiosurgery delivered with CyberKnife can target the thrombus inside the vein while sparing the vessel wall, and combining local treatment of that kind with targeted or immunotherapy drugs has produced meaningful tumour shrinkage in patients who were initially told nothing could be done. The realistic goal in this situation is control, and control sometimes exceeds expectations.

What is the difference between the stage and the liver function score?

The stage describes the tumour — how large it is, how many tumours there are, and whether it has entered the portal vein or spread elsewhere. The function score, most often Child-Pugh, describes the liver itself: how well it is still doing its job. Both are needed because they answer different questions. A treatable tumour in a failing liver and a treatable tumour in a healthy liver are different clinical problems, and the same treatment is not appropriate for both.

How quickly can I get an opinion as an international patient?

Once your records are complete, our liver cancer panel reviews the case and returns a written assessment with treatment options, an indicative timeline and a cost estimate, usually within 48 hours. Complete means the imaging in digital format, the tumour marker and liver function results, and any pathology or molecular report you already have. You can then decide about travelling, with no obligation.

Patient Stories

Stories from our liver cancer programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Get a personalized liver cancer plan in 48 hours

Send us your multiphase contrast CT or MRI, your AFP and liver function results, and any pathology report you already have. Our liver cancer panel reviews the case together and returns a written assessment of the options that apply to your tumour and your liver.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*